07:00 Thu 22 Oct 2020
Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and
To participate, please dial one of the following numbers and reference conference ID 2469127:
- +1-888-317-6003 for callers in
the United States - +1-412-317-6061 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and an audio replay will be available there for 90 days.
For further information, please contact:
Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
info@veronapharma.com | |
N+1 Singer (Nominated Adviser and | Tel: +44 (0)20 7496 3000 |
Optimum Strategic Communications (European Media and Investor Enquiries) | Tel: +44 (0)203 950 9144 verona@optimumcomms.com |
Mary Clark / | |
Argot Partners ( | Tel: +1 212-600-1902 verona@argotpartners.com |
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. The Company raised gross proceeds of
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE